Chemo with or without immunotherapy for peritoneal mesothelioma
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding immunotherapy to standard chemotherapy helps people with peritoneal mesothelioma, a cancer in the lining of the abdomen. You may receive chemotherapy alone or with immunotherapy, and the goal is to improve cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed malignant peritoneal mesothelioma and have not had any prior treatment for it
- Your cancer can be measured on scans (doctors can track its size or spread)
- You must be able to consent and have good enough strength for treatment (ECOG 0–1)
- Your blood counts and organ tests must be high enough (white cells, neutrophils, platelets, kidney and liver tests)
- You must not be pregnant or breastfeeding, and if you can get pregnant, you must use reliable birth control
- You cannot have certain other serious illnesses (like uncontrolled infection or major heart disease) or active autoimmune/immune problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
Hear when a new Peritoneal Malignant Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.